HEALIOS K.K. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145 JPY | 0.00% |
|
-9.38% | -12.12% |
| Apr. 10 | Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen | MT |
| Apr. 09 | Healios K.K. Enters into Joint Research Agreement with AND Medical Group | CI |
| Sales 2024 * | 910M 5.88M | Sales 2025 * | 1.38B 8.9M | Capitalization | 13.07B 84.52M |
|---|---|---|---|---|---|
| Net income 2024 * | -2.69B -17.41M | Net income 2025 * | -2.41B -15.6M | EV / Sales 2024 * | 13.5 x |
| Net cash position 2024 * | 822M 5.32M | Net Debt 2025 * | 608M 3.93M | EV / Sales 2025 * | 9.94 x |
| P/E ratio 2024 * |
-4.37
x | P/E ratio 2025 * |
-4.74
x | Employees | 64 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.62% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -9.38% | ||
| Current month | -9.94% | ||
| 1 month | +10.69% | ||
| 3 months | -7.05% | ||
| 6 months | -10.49% | ||
| Current year | -12.12% |
1 week
137.00
153.00
1 month
133.00189.00
Current year
114.00189.00
1 year
114.00332.00
3 years
114.002 557.00
5 years
114.002 557.00
10 years
114.002 669.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hardy Kagimoto
CEO | Chief Executive Officer | 47 | 11-02-23 |
Richard Kincaid
DFI | Director of Finance/CFO | 47 | 18-02-28 |
Masanori Sawada
CTO | Chief Tech/Sci/R&D Officer | 42 | 12-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 62 | 12-12-31 | |
| Director/Board Member | 71 | 18-02-28 | |
Hardy Kagimoto
CEO | Chief Executive Officer | 47 | 11-02-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 145 | 0.00% | 1 321 400 |
| 24-04-18 | 145 | +0.69% | 796,700 |
| 24-04-17 | 144 | -2.04% | 789,200 |
| 24-04-16 | 147 | -0.68% | 1,540,300 |
| 24-04-15 | 148 | -3.27% | 1,145,200 |
Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT
More quotes
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
145
JPY
Average target price
280
JPY
Spread / Average Target
+93.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.12% | 84.54M | |
| -3.11% | 102B | |
| +1.70% | 96.07B | |
| -1.80% | 21.66B | |
| -17.80% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -27.79% | 13.79B | |
| -0.36% | 13.33B | |
| +19.31% | 10.94B |
- Stock Market
- Equities
- 4593 Stock
